Disclaimer

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS NOT PERMITTED UNDER THE LAW OF THAT JURISDICTION.

This document has been prepared by Genscript Biotech Corporation (the "Company") for a limited number of recipients and for information purposes only. The information relating to the Company, its subsidiaries and affiliates, and their respective businesses and assets contained in this document has not been independently verified. This document does not purport to provide a complete description of the matters to which it relates. Some of the information is still in draft form and will only be finalized at the time of publication of the relevant prospectus or offering circulars of the Company. No reliance shall be made in relation to the information contained in this document. No representation, warranty or undertaking, express or implied, is or will be made in, or in relation to, and no responsibility or liability (including, without limitation, any liability in negligence) is or will be accepted by the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, or any of their shareholders, directors, officers, employees, affiliates, advisors or representatives as to, or in relation to, this document or the accuracy, fairness, reasonableness, correctness, or completeness of the information or opinions contained herein or any other information or opinions, whether written or oral, made available to any interested party or its advisors and any liability for any loss however arising from any use of this document or its contents or otherwise arising in connection with this document therefore is hereby expressly disclaimed. The information contained in this document should be considered in the context of the circumstances prevailing at the time and is subject to change without notice. By preparing this document, none of the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, or any of their shareholders, directors, officers, employees, affiliates, advisors or representatives undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent.

This document contains information that the Company’s current beliefs and expectations about the future as of the respective dates indicated herein. These forward-looking statements are based on a number of assumptions about the Company’s operations, information currently available to the Company, and factors beyond the Company’s control and are subject to significant risks and uncertainties, and, accordingly, actual results may differ materially from these forward-looking statements. The Company undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates.

This document does not constitute or form part of, and should not be construed as, an offer to sell or issue or a solicitation of an offer to purchase or subscribe for any securities of the Company nor shall there be any sale of such securities in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country. Public offering of securities to be made in the United States must be made by means of a prospectus that may be obtained from the issuer or the selling security holder and that contains detailed information about the issuer, its management and financial statements. No securities of the Company have been, or will be, registered under the US Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or other jurisdiction of the United States and no securities of the Company may be offered or sold, directly or indirectly, in the United States, except pursuant to a registered offering in compliance with or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and the applicable securities laws of any state or other jurisdiction of the United States. In Hong Kong, no securities of the Company may be offered to the public unless a prospectus in connection with the offering for sale or subscription of such securities has been authorized by The Stock Exchange of Hong Kong Limited for registration by the Registrar of Companies in Hong Kong under the provisions of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32 of the Laws of Hong Kong), and has been so registered. No part of this document shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto. Any decision to purchase any securities of the Company in any offering for sale, distribution or subscription (as the case may be) in any state or other jurisdiction of the United States, Hong Kong or anywhere else should be made solely on the basis of information contained in the relevant prospectuses or offering circulars of the Company which will be published in due course. The recipients and readers of this document should not construe the contents of this document as legal, tax, accounting or investment advice and should consult their own financial, tax, accounting or legal advisors or other consultants in case of doubt. This document, and any further information made available to you, are highly confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed to any other person, directly or indirectly.

This document must not be copied, reproduced, distributed or passed, in whole or in part, to any other person, directly or indirectly, at any time, by any medium, in any form, for any purpose without the prior written consent of the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. Unauthorized copying or reproduction, or redistribution of this document or any information contained herein to any person, could result in material delay to, or otherwise prejudice the success of the global offering of the Company. No part of this document may be distributed, reproduced, taken or transmitted into the United States, Canada or Japan, or to any resident thereof. You acknowledge and represent to the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers that you are a professional investor, have the knowledge, experience and capability to conduct your own assessment of the Company and its securities and that you have conducted your own investigation with respect to the Company and its securities and have obtained or will obtain your own independent advice relating to any investment in the securities of the Company.

By accepting delivery of this document or the information contained herein, you are deemed to represent to the Company, Sole Sponsor, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers, and their shareholders, directors, officers, employees, agents, affiliates, advisors and representatives, that you are and will continue to be, a person who is not a professional investor or any person who is representing, if any, a person outside the United States within the meaning of Regulation S under the US Securities Act, or a professional investor within a category of person described in the Securities and Futures (Professional Investor) Rules (Chapter 571D of the Laws of Hong Kong).

By accepting delivery of this document or the information contained herein, you are agreeing that you have read and agree to comply with the requirements of this disclaimer; (ii) you will maintain absolute confidentiality regarding this document and the information contained herein; and (iii) you will not make direct contact with (a) the Company’s customers, partners or subcontractors; (b) any governmental, administrative or regulatory bodies which supervise or regulate the Company or (c) employees of the Company in order to seek non publicly available information of the Company.
Company Overview

Business Highlights
Financial Highlights
Future Strategy
Q&A
Mission

Make Humans and Nature Healthier through Biotechnology
Global Development Footprint

- **GenScript** Founded in New Jersey
- **KPCB / TBIG** Healthcare investment
- **Introduced Custom Protein and Antibody Service**
- **Established research and production center in Nanjing, China**
- **New Nanjing** research and production facility opened
- **Selected as the sole business entity to participate in the Synthetic Yeast Genome Sc2.0 Project**
- **Established subsidiary in Japan**
- **Employee headcount reached 1,000**
- **GenScript** Founded
- **Launched Bestzyme Biotech industrial synthetic biology product** segment
- **2009**
- **2011**
- **2013**
- **Launched Legend Biotech (the Cell Therapy Segment)**
- **CRO Leadership award**
- **2014**
- **Launched the MM Program received IND clearance in US and China**
- **Recruitment for JNJ-68284528 and LCAR-B38M Program is in progress in both US & China**
- **Biologics CDMO business well recognized by academic and industrial community and BDBU was officially established**
- **Global headcount reached to over 2600**
- **2015**
- **2016**
- **2017**
- **2018**
- **Merged Nornoon Company**
- **CFDA accepted the application for investigational new drug by Legend**
- **Acquired 100% of the issued shares of CustomArray**
- **Launched Legend Biotech (the Cell Therapy Segment)**
- **KPCB / TBIG Healthcare investment**
- **Established subsidiary in Japan**
- **Employee headcount reached 1,000**
- **GenScript** Founded in New Jersey
- **Introduced Custom Protein and Antibody Service**
- **Established research and production center in Nanjing, China**
- **New Nanjing** research and production facility opened
- **Selected as the sole business entity to participate in the Synthetic Yeast Genome Sc2.0 Project**
- **Established subsidiary in Japan**
- **Employee headcount reached 1,000**
- **GenScript** Founded
- **Launched Bestzyme Biotech industrial synthetic biology product** segment
- **2009**
- **2011**
- **2013**
- **Launched Legend Biotech (the Cell Therapy Segment)**
- **CRO Leadership award**
- **2014**
- **Launched the MM Program received IND clearance in US and China**
- **Recruitment for JNJ-68284528 and LCAR-B38M Program is in progress in both US & China**
- **Biologics CDMO business well recognized by academic and industrial community and BDBU was officially established**
- **Global headcount reached to over 2600**
- **2015**
- **2016**
- **2017**
- **2018**
- **Merged Nornoon Company**
- **CFDA accepted the application for investigational new drug by Legend**
- **Acquired 100% of the issued shares of CustomArray**
Business Blueprint – Incubating the Future

New Area of Business Development
Generating Higher Return

Core Business Generating Cash Flow
For Future Development

GenScript Proprietary Technologies

CAR T-Cell Immunotherapy
Industrial enzymes

Life sciences research and application services and products

Gene synthesis
Company Positioning & Major Achievements

- Become Global Leader in Gene Synthesis Services and Synthetic Biology Products;
- Become world class leader in Cell Therapy and Gene Therapy fields

**Major Achievements**

- Group Sales Revenue increased over 50%;
- Expanded global leading position in Gene Synthesis Services;
- Successfully launched antibody purification devices;
-Received FDA & China FDA clearance to initiate clinical trials with JNJ-68284528 / LCAR-B38M for treatment of Multiple Myeloma;
-US Phase 1b clinical trial has been running as planned, and entitled to First milestone payment US25M;
-FDA has granted the Orphan Drug Designation to JNJ-68284528 / LCAR-B38M;
-EMA has granted the PRIME designation to JNJ-68284528 / LCAR-B38M;
-Finished Preparation for China Clinical trials;
-Built up world class management team for Legend;
-Constructing US and PRC GMP facilities as planned;
-Reached strategical collaboration with Biologists CDMO partners;
-Finished the construction of Industry Enzyme manufacture facility;
Company Overview

Strong IP Position

- Strong IPs and know-how proprietary technology in the area of synthetic biology;
- Holds 70+ registered patents and 200+ patent application; 1

Global Presence

- New Jersey-USA
- Nanjing-China
- Amsterdam-Netherland
- Dublin-Ireland
- Tokyo-Japan;

Diversified Customer Base

- 5,000+ customers globally
- Including global pharmaceutical and biotech companies, colleges and universities, research institutes, government organizations and distributors in over 100 countries;

Well Trained Employees

- Over 2,600 employees globally; 1
- Over 75% of employees hold Bachelor and above degrees,
- Over 33% of employees hold Master and PHD degrees

1. As at Dec 31, 2018
Content

Company Overview

Business Highlights

Financial Highlights

Future Strategy

Q&A
Strategic Business Positioning

**Life Science CRO**
Continuously Being the Global Leader in Gene Synthesis Services Market

**Biologics CDMO**
Becoming an Emerging Leader of CDMO Service provider

**Industrial Synthetic Biology Products**
Make the best Enzyme products to improve the quality of life and maintain a better nature environment

**Cell Therapy**
The Pursuit of A Cure

**Gene Synthesis Technology**
One Stop Life Science CRO Solution

Gene Synthesis
DNA Sequencing

Peptide Synthesis

Global Leader in Gene Synthesis
- Largest gene synthesis provider;
- Successful delivery of more than 1.2M genes;
- Largest capacity at 100 million bp/month;
- Successful rate 99.95%;
- Over 98.5% on-time delivery;

Becoming the Largest Oligo Provider in Precise Medicine
- Rich experience and solid foundation in oligo synthesis over past 16 years;
- Supply oligo in most promising health territory, precise medicine;
- MDx oligo (US$ 427.8M addressable market);
- MDx Kits (US$1,100M addressable market);

CRO Products

Antibody Development

Continuously Enhanced CRO Core Competitiveness
- Molecular Cloud
- Rabbit Monoclonal Antibodies
- Combinatorial Library
- CRO Automation
Solving Biologics Drug Industry Challenge

Protein Purification Solution

- 96 well Magnetic plate

- Collaboration with Amgen, We developed the innovative Mag beads capture instrument for antibody purification

- Able to provide high throughput capability without prior centrifugation and filtration of samples.

- Becoming the first player in the commercial magnetic bead technology market to address this need

- Priced at USD70K per unit.
**Biologics CDMO Builds up Advanced Tech Platform**

- Gene & Peptide synthesis
- Antibody production
- Protein production
- Cell line engineering
- Crispr KO/KI engineering

**From Target to IND**

- **GMP-Compliant Manufacturing**
- **Target Assessment & Validation**
- **Ab Lead Generation & Characterization**
- **Stable Cell Line Dev. & Process Dev**
- **Ab Lead Optimization**

- **321 therapeutic antibody leads generation**
- **129 humanization projects delivered**
- **4 INDs & 1 in Clinical trial**
- **28 cell line & process development projects delivered**

**Key Performance Indicators**

- **321** therapeutic antibody leads generated
- **129** humanization projects delivered
- **4 INDs & 1 in Clinical trial**
- **28** cell line & process development projects delivered
- **4** INDs & **1** in Clinical trial
SMAB Platform to Enable Client Success

Bispecific Antibody Platform-SMAB

- **Naïve**: sequence mutation not needed, minimum gene editing;
- **Outstanding developability**, as good as Monoclonal Ab;
- **Low immunogenicity, less side effects**;
- **Flexible format**: ≥ 2 targets/epitopes;
- **Unique molecular flexibility** for precise adjustment of dual target effects

Commercial Collaboration

- **3 Partners** on SMAB Platform;
- License and further development of **2 SMAB-based antibody drug molecules**;
- License and development of **1 biosimilar**;
- Strategic partnership on **PD, PK & toxicity assessment**;
- Strategic partnership on full-humanized mouse antibody discovery
Promising Market Prospectus for Biologics CDMO

2018

- Biologics R&D: $44B
- Preclinical CRO Market: $1.7B
- Clinical CRO Market: $8.6B
- CMO Market: $9.7B
- Biologics Manufacture: $70B

Addressable Market

From US$1.7B uplifting to US$22B

2022

- Biologics R&D: $63B
- Preclinical CRO Market: $3.3B
- Clinical CRO Market: $16.9B
- CMO Market: $18.9B
- Biologics Manufacture: $110.1B

From US$1.7B uplifting to US$22B
Investment in CDMO GMP Facilities to Fuel up Growth

1. From an idea to preclinical
   - Full cycle of Services
   - Antibody Discovery,
   - Cell line development, Formation and engineering, assay development
   - Preclinical development

2. Enabling Clinical Trials
   - Compliant to GMP regulation in US, CN and EU
   - For Clinical I/II

3. Extending to Commercial manufacturing (incl: plasmid & virus)
   - Compliant to GMP regulation in US, CN and EU
   - For Clinical III and Commercial manufacturing
Committed to “Make the Best Enzyme”

**Comprehensive R&D Competences**
- **R&D capacity** to enable the launch of new products efficiently
- Latest Gene-editing technology (Crispr/Cas9) enhanced
  Comprehensive expression platform

**Production Facility Building up & Optimization**
- Production capacity reached 150,000 standard tons.
- Optimization of production processes will improve the competitiveness of our products

**Enhance Commercial Competences**
- Recruited industrial experts to lead the commercial team
- Establish long-term partnership with influential customers
Introduction of CAR-T Cell Therapy

1. Leukapheresis
2. T-cell activation / transduction
3. Modified T-cell expansion
4. Chemotherapy
5. Modified T-Cell infusion
Cell Therapy – Helping to improve the lives of patients worldwide

US & China Regulatory Approval

• Received FDA & CFDA clearance to initiate clinical studies with JNJ-68284528 / LCAR-B38M for treatment of Multiple Myeloma;

• FDA has granted the Orphan Drug Designation to JNJ-68284528 / LCAR-B38M

• EMA has granted the PRIME designation to JNJ-68284528 / LCAR-B38M

US & China Clinical Progress

• US Phase 1b clinical trial has been running as planned, first batch of milestone payment US$25M received

• China Phase 2 Confirmatory Trial has been initiated since Feb 2019

US & China GMP Facility

• China GMP facility has been up and running and LCAR-B38M for Phase 2 clinical trial has been initiated as planned;

• US GMP facility for pivotal study and commercial supply will be ready for operation in Q2, 2019 as planned.

*Companies mentioned are former company experiences*
## Build Up World Class Management Team for Legend

<table>
<thead>
<tr>
<th>Function</th>
<th>US</th>
<th>China</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CEO</strong></td>
<td>Yuan Xu - Merck, Gilead, Novartis, Amgen, GSK, Genentech</td>
<td></td>
</tr>
<tr>
<td><strong>R&amp;D</strong></td>
<td>Qiong Wang AstraZeneca, NCI</td>
<td>Frank Fan, Simon Wu GenScript</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td>Syed Rizvi Celgene, Novartis, Merck</td>
<td>Tracy Luo Amgen, AstraZeneca</td>
</tr>
<tr>
<td><strong>Commercial</strong></td>
<td>Steve Gavel Celgene, Millennium, IMS Health, Amgen</td>
<td>Chong Yang Roche, Bayer, Novartis</td>
</tr>
<tr>
<td><strong>Manufacturing</strong></td>
<td>Jason Hamilton, John Tomtishen Novartis, Fox Chase Cancer Center</td>
<td>David He Boehringer Ingelheim</td>
</tr>
<tr>
<td><strong>Global Quality</strong></td>
<td>Alan Kick - Celgene, Dendreon, Pfizer, JNJ, Roche</td>
<td>Yuhong Qiu - Novartis, JNJ</td>
</tr>
<tr>
<td><strong>Global Regulatory</strong></td>
<td></td>
<td>Yuhong Qiu - Novartis, JNJ</td>
</tr>
<tr>
<td><strong>Global Business Development</strong></td>
<td></td>
<td>Meeta Chatterjee – Merck, Schering-Plough</td>
</tr>
</tbody>
</table>
Global Clinical Trial Updates\(^1\)

**US & Europe Clinical Trial Updates\(^1\)**

**Overview**
- Phase: 1b/2
- Purpose: Phase 1b to test safety and to determine the dosage of phase 2; Phase 2 to test efficacy

**Planned Enrollment**
- 110 participants

**US Trial Location-Recruiting**
- Sarah Cannon Research Institute – Nashville, TN
- Mount Sinai Medical Center – New York, NY
- Levine Cancer Institute – Charlotte, NC
- University of Chicago – Chicago, IL

**Worldwide Trial Location-Not yet recruiting**
- United States (13 additional sites)
- Belgium (3 sites)
- France (3 sites)
- Israel (2 sites)
- Netherlands (3 sites)
- Spain (3 sites)

**Current Status**
- Patient Treatments on going as planned

**China Clinical Trial Updates\(^1\)**

**Overview**
- Phase: 2
- Purpose: To test safety and efficacy

**Planned Enrollment**
- 60 participants

**China Trial Location-Recruiting**
- 上海交通大学医学院附属瑞金医院
- 浙江大学医学院附属第一医院

**Worldwide Trial Location-Not yet recruiting**
- 江苏省人民医院
- 西安交通大学第二附属医院
- 四川大学华西医院
- 福建医科大学附属协和医院
- 北京大学第三医院
- 上海长征医院

**Current Status**
- Patient Treatments triggered off as planned

1: as of 20 Mar 2019
2: For more information please visit: https://www.clinicaltrials.gov/ct2/show/record/NCT03548207?conds=MultipleMyeloma&draw=2&rank=3&view=record
http://www.chinadrugtrials.org.cn/eap/clinicaltrials.searchlistdetail
Multiple Myeloma Prevalence and Market Potential

230,000 5-year worldwide prevalence
1% of worldwide new cancer cases
2.1% of all US cancer deaths

50.7%
5-year survival rate

US$ 29 B

World Wide MM Market, 2022E

- Revlimid
- Velcade
- Pomalyst
- Kyprolis
- Darzalex
- Other

• US contributed 62% of the total sales, about $8.7 Billion

1. Source: EVP MM treatment regimen approvals; GlobalData Pharmaceutical Intelligence https://pharma.globaldata.com/HomePage/Index
Fully Integrated Capability and Global Footprint

Fully Integrated Capability
- R&D
- Clinical
- Commercial
- Manufacturing

Legend Biotech

Legend Global R&D Strategy
- Core Technology
  - CAR
  - TCR
- Product Platform
  - Autologous
  - Allogeneic
- Disease Areas
  - Hematologic Malignancies
  - Solid Tumors
  - Infectious Diseases
  - Autoimmune Diseases
2019-20 Cell Therapy Pipeline Advancement

Current Pipeline

LCAR-B38M Ph 2 Trials in US/EU/China

Worldwide Collaboration with Janssen

Future Pipeline

AML | Lymphoma | Gastric Cancer | Ovarian Cancer | Infectious Disease

First-in-Human Studies: Next Generation CAR-T/TCR-T/Allogeneic Platforms

Clinical Plan

Multiple IIT programs in China

Multiple IND programs in US
Content

Company Overview
Business Highlights
Financial Highlights
Future Strategy
Q&A
Financial Highlights

<table>
<thead>
<tr>
<th></th>
<th>2017 (US$M)</th>
<th>2018 (US$M)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>152.6</td>
<td>231.0</td>
<td>51.3%</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>104.6</td>
<td>158.5</td>
<td>51.6%</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>68.5%</td>
<td>68.6%</td>
<td></td>
</tr>
<tr>
<td>Net Profit</td>
<td>27.0</td>
<td>20.8</td>
<td>(23.1 %)</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>18.1</td>
<td>74.1</td>
<td>309%</td>
</tr>
<tr>
<td>CAPEX</td>
<td>32</td>
<td>79.6</td>
<td>148.8%</td>
</tr>
<tr>
<td>Cash Position¹</td>
<td>127.3</td>
<td>577.3</td>
<td>353.7%</td>
</tr>
</tbody>
</table>

- Fast growth in top line even excluding legend portion, recorded 30+% growth in 2018;
- Solid and stable gross margin;
- Significant increase in research and development expense;
- Intensive capital investing in legend and other innovation business;
- Strong cash position.

1. Cash Position=Financial assets at fair value through profit or loss+Cash and cash equivalents+Pledged short-term deposits + Available for sale investments
51%+ Growth in Revenue and Gross Profit

Revenue by Business Segments (US$ M)

- 4 consecutive years of revenue growth since listing, showing strong momentum;
- Continued growth & success in 4 focused business segments
- Grow revenue in Bio-Science services and products segment above market average
- Create value through strategic collaboration in biologics development services segment
- Sustainable revenue contribution from upfront payment and milestone payment of JNJ collaboration
Significant Increase in R&D

- Invested US$74M+ in R&D, increased by 3 times;
- 4 year CARG is at 118.53%;
- Invest in Cell therapy US$55M+:
  - Groundbreaking cell therapy platform for the treatment of cancer;
  - Lead program, LCAR-B38M (BCMA), IND program in both US and China;
  - Multiple additional programs under development;
- Invest in Bio-Science and other innovation:
  - Development of gene synthesis chip and magnetic beads
  - Portfolio optimization
Intensively Capital Expenditure in 2018

2018 Fixed Assets\(^1\)
Increase and Depreciation (US$ M)

Capital Expenditure increased by 149% to US$79.6M

- **Invest in Bio-Science**
  - High throughput and automation renovation in gene synthesis;
  - New production system implantation of industry oligo;
  - Biological GMP facility build up;

- **Invest in Cell therapy**
  - GMP facilities readiness for Clinical trial both in US and China;
  - Research and development equipment;

- **Infrastructures**
  - Zhenjiang land and construction;
  - Nanjing Legend land and construction;
  - Warehouse and staff facilities;

<table>
<thead>
<tr>
<th></th>
<th>Fixed Asset Addition</th>
<th>Fixed Asset Depreciation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>41</td>
<td>6</td>
</tr>
<tr>
<td>2018</td>
<td>91</td>
<td>11</td>
</tr>
</tbody>
</table>

\(^1\) PROPERTY, PLANT AND EQUIPMENT=
Company Overview
Business Highlights
Financial Highlights

Future Strategy
Q&A
Company Strategy

- **R&D Enhancement**
  - Increasing effort to Cell therapies.
  - Expand the application of our SMAB platform.
  - Further strengthen our global leading position in gene synthesis and other life sciences technology products and services.

- **Production Capacity Expansion**
  - Expand the GMP production capacity to enable fully integrated biological drug development and manufactory capability.
  - Expand the Cell Therapy GMP production capacity for the upcoming global launch.

- **Global Market Penetration**
  - Establish Cell Therapy commercial team.
  - Strengthen the collaboration with Biotech and Biopharma community.
  - Further consolidate our leading position on Molecular biology services.

- **Strategic Acquisition**
  - Pursue strategic acquisitions of cutting-edge techniques and business entities, in order to complement the existing internal capacity and to speed up the overall growth.
Thanks

Genscript Biotech Corporation

Make People and Nature Healthier through Biotechnology

For More Information: https://www.genscript.com/

IR Contact E-mail: IR@genscript.com